Related Experiment Video
Updated: Mar 25, 2026

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through
Kacie A Gardella1, Israel Muro2, Gloria Fang2
1Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX, USA.
Abstract:
The aryl hydrocarbon receptor nuclear translocator (ARNT) is involved in xenobiotic and hypoxic responses, and we previously showed that ARNT also regulates nuclear factor-κB (NF-κB) signaling by altering the DNA binding activity of the RelB subunit. However, our initial study of ARNT-mediated RelB modulation was based on simultaneous suppression of the two ARNT isoforms, isoform 1 and 3, and precluded the examination of their individual functions. We find here that while normal lymphocytes harbor equal levels of isoform 1 and 3, lymphoid malignancies exhibit a shift to higher levels of ARNT isoform 1. These elevated levels of ARNT isoform 1 are critical to the proliferation of these cancerous cells, as suppression of isoform 1 in a human multiple myeloma (MM) cell line, and an anaplastic large cell lymphoma (ALCL) cell line, triggered S-phase cell cycle arrest, spontaneous apoptosis, and sensitized cells to doxorubicin treatment. Furthermore, co-suppression of RelB or p53 with ARNT isoform 1 prevented cell cycle arrest and blocked doxorubicin induced apoptosis. Together our findings reveal that certain blood cancers rely on ARNT isoform 1 to potentiate proliferation by antagonizing RelB and p53-dependent cell cycle arrest and apoptosis. Significantly, our results identify ARNT isoform 1 as a potential target for anticancer therapies.
Insights
Certain blood cancers overexpress aryl hydrocarbon receptor nuclear translocator (ARNT) isoform 1, driving proliferation. Suppressing ARNT isoform 1 halts cancer growth and increases sensitivity to chemotherapy.
Area of Science:
- Molecular Biology
- Cancer Biology
- Cell Signaling
Background:
- The aryl hydrocarbon receptor nuclear translocator (ARNT) regulates xenobiotic and hypoxic responses.
- ARNT modulates nuclear factor-κB (NF-κB) signaling via the RelB subunit.
- Previous studies could not differentiate the roles of ARNT isoforms 1 and 3.
Purpose of the Study:
- To investigate the distinct roles of ARNT isoform 1 and 3 in lymphoid malignancies.
- To determine the impact of ARNT isoform 1 on cancer cell proliferation and survival.
- To explore ARNT isoform 1 as a potential therapeutic target in blood cancers.
Main Methods:
- Comparative analysis of ARNT isoform levels in normal lymphocytes versus lymphoid malignancies.
- Functional studies involving ARNT isoform 1 suppression in multiple myeloma (MM) and anaplastic large cell lymphoma (ALCL) cell lines.
- Assessment of cell cycle progression, apoptosis, and drug sensitivity following ARNT isoform 1 manipulation.
- Co-suppression experiments with RelB or p53 to elucidate ARNT isoform 1's mechanism of action.
Main Results:
- Lymphoid malignancies show elevated ARNT isoform 1 levels compared to normal lymphocytes.
- Suppression of ARNT isoform 1 induced S-phase cell cycle arrest and apoptosis in MM and ALCL cells.
- ARNT isoform 1 suppression sensitized cancer cells to doxorubicin treatment.
- Co-suppression of RelB or p53 with ARNT isoform 1 abrogated cell cycle arrest and doxorubicin-induced apoptosis.
Conclusions:
- Elevated ARNT isoform 1 is crucial for the proliferation of certain blood cancers.
- ARNT isoform 1 promotes cancer cell survival by antagonizing RelB and p53-dependent pathways.
- ARNT isoform 1 represents a promising therapeutic target for treating specific lymphoid malignancies.
Related Concept Videos
Abnormal Proliferation
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules
Regulation of Nuclear Protein Sorting

